Bone health in children with congenital adrenal hyperplasia
Not Applicable
- Conditions
- Health Condition 1: E250- Congenital adrenogenital disordersassociated with enzyme deficiency
- Registration Number
- CTRI/2024/08/071947
- Lead Sponsor
- Maulana Azad Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Diagnosed cases of Congenital adrenal hyperplasia aged 5-18 years
Exclusion Criteria
Patients with inherent bone conditions
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To measure markers of bone mineral metabolism Calcium, Phosphate, Alkaline Phosphatase, Vitamin D, Parathyroid Hormone (PTH) and Osteocalcin in patients with Congenital Adrenal Hyperplasia in children and adolescents aged 5-18 yearsTimepoint: To measure markers of bone mineral metabolism Calcium, Phosphate, Alkaline Phosphatase, Vitamin D, Parathyroid Hormone (PTH) and Osteocalcin in patients with Congenital Adrenal Hyperplasia in children and adolescents aged 5-18 years who are already on steroids since birth on follow up stat sample taken on Day 1
- Secondary Outcome Measures
Name Time Method In children with Congenital Adrenal Hyperplasia <br/ ><br>1. To evaluate the association of these markers with projected adult height <br/ ><br>2. To study the association of these markers with duration, dose and type of steroids <br/ ><br>3. To correlate the levels of these markers with Tanner Staging in age group of 9-18 yearsTimepoint: Baseline